Reportlinker Adds The Australian Pharmaceutical Market Outlook to 2015: Policy environment, market analysis, key trends, growth opportunities and competitive landscape

Jul 06, 2010, 09:03 ET from Reportlinker

NEW YORK, July 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Australian Pharmaceutical Market Outlook to 2015: Policy environment, market analysis, key trends, growth opportunities and competitive landscape

http://www.reportlinker.com/p0233960/The-Australian-Pharmaceutical-Market-Outlook-to-2015-Policy-environment-market-analysis-key-trends-growth-opportunities-and-competitive-landscape.html

Australia is the most attractive market for pharmaceutical investment in the Asia Pacific region which is primarily due to its growing and ageing population, excellent access to medicines, and fast-recovering economy.

Life expectancy in Australia is 79.2 years for males and 84.1 years for female which is among the highest in the world. High life expectancy amongst Australians has led to an increase in lifestyle diseases resulting in an increase in healthcare spending. In 2009, cancer, cardiovascular diseases, diabetes, respiratory diseases (COPD, Asthma), musculoskeletal disease, neurological disorders (dementia), mental disorders, remained the leading cause of health problems in the country.

Funding for health goods and services in Australia comes from various sources such as the Australian government, local governments and non government agencies. In 2005-06 period, the major funding came from two levels of government, which accounted for 68% of the total healthcare expenditure. Australian federal government followed by local government was the major contributors accounting for 43% and 25% of the total funding respectively (AIHW).

The Therapeutic Goods Act of 1989 is the core of market regulation in Australia. The objective of this act is to ensure that Australians get medicines and medical devices which are safe and are of high quality, and match standards equal to that of comparable countries. This act also provides a nation wide regulatory outline for therapeutic goods and ensures the quality, safety, and efficacy of medicines and medical devices. All medical products which come in or are exported from Australia are registered with the ARTG (Australian Register of Therapeutic Goods).

Key features of this report

- Macroeconomic environment in Australia includes the demographic trends, economic landscape, disease burden and healthcare spending

- Australian healthcare system involving the pharmaceutical spending, intellectual property regime, pricing and reimbursement, healthcare reforms, and recent development in the healthcare sector

- Overview of the Australian pharmaceutical market covering comparative dynamics of major pharmaceutical market, key recent events, therapeutic area analysis, leading product dynamics, generic drug market and the overall market forecast through 2015

- Forecasts and analysis of the leading products in the Australian pharmaceutical market over the period 2009–15 spread across major indications and classes of treatments

Scope of this report

- Develop insights for the Australian pharmaceutical market, pricing & regulation, healthcare system and detailed epidemiological status of the common indications/risk factors in the country

- Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges in the Australian market

- Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Australian pharmaceutical market

- Compare the franchises of leading pharmaceutical players across major indications, and understand how market share of leading companies will change in the next 6 years

Key Market Issues

- The Australian economy grew by 1.5% during the first three quarters of 2009: In 2009, a fiscal stimulus package of over $50bn was introduced to reduce the effect of slowing world economy by the Executive Government of Australia under prime ministership of Kevin Rudd. Increasing demand for commodities from China along with the policy reforms done by the government has helped Australian economy regain buoyancy after just one quarter of decline in growth. The Australian economy grew by 1.5% during the first three quarters of 2009, which was the best performance in OECD (Organization for Economic Co-operation and Development).

- New PBS reforms, insulates certain drugs from reference pricing: Recent changes in the pricing policy shows a shift towards rewarding innovation. Since August 2007, the PBS has been divided into two formularies F1 and F2. F2 drugs will have the price cuts whereas F1 drugs are insulated from reference pricing, even if the mechanism of action of a F1 dug is similar to that in F2. F1 drugs which do not have bioequivalent brands can maintain higher prices according to the new formularies.

- Australian government approved 45% refundable tax credit for R&D companies: Biotechnology research in Australia continues to receive funding from both federal and state governments in Australia (New Zealand trade and enterprise report, January 2009). Apart from the Australian government's Innovation Investment Follow-on Fund (IIFF, a venture capital fund) in May 2009, the government approved the 45% refundable tax credit for R&D, applicable for companies with a turnover of under $16.7m (Australian dollar, (AUD) 20m). Moreover, IIFF is targeted to address the lack of capital available to the most promising and innovative companies.

Key findings from this report

- According to 2008 AIHW (Australian Institute of Health and Welfare) report, high life expectancy (second only to Japan) and an increasingly aged population has led to an increase in lifestyle diseases resulting in an increase in healthcare spending. Approximately one in every five adult Australians (nearly 4m people) has some or the other disability and more than 1m people need assistance with their daily activities.

- The Australian pharmaceutical market was valued at around $9bn in 2009 and includes both domestic manufacturers and large pharmaceutical companies, with the latter having a direct base in the country through R&D and marketing. Among foreign players, Pfizer, AstraZeneca, Sanofi-Aventis and Novartis dominated the Australian pharmaceutical market in 2009.

- Cardiovascular disorders, led by Lipitor (Pfizer) and Crestor (AstraZeneca) remained the major therapeutic area in the Australian pharmaceutical market. Cholesterol and triglyceride regulating preparations, angiotensin II inhibitors, ACE inhibitors (plain), were the leading drug classes in the cardiovascular therapy in 2009.

- CNS disorders, led by Zyprexa (Eli Lilly) remained the other leading therapy area in the Australian pharmaceutical market. Antipsychotics, anti-depressants, and mood stabilizers were the major drug classes in this therapy area registering over $250m sales each in 2009.

Key questions answered

- What will be the major growth indications and the accompanying growth drivers in the Australian pharmaceutical industry over the next 6 years?

- Which were the leading players in the Australian pharmaceutical market (both multinational and domestic) in 2009?

- Which products will be the future growth drivers for the Australian pharmaceutical market?

- Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?

- How is the competitive landscape of key therapeutic areas in Australia?

Table of Contents

The Australian pharmaceutical market outlook to 2015

Executive Summary 10

The Australian macroeconomic environment 10

The Australian healthcare system 11

Market analysis 11

Competitive landscape 12

Chapter 1 Scope and methodology 16

Chapter 2 The Australian macroeconomic environment 18

Summary 18

Introduction 19

Demographic trends in Australia 19

Economic landscape of Australia 20

Disease burden 22

Healthcare spending 24

Chapter 3 The Australian healthcare system 28

Summary 28

Introduction 29

Healthcare system 29

Healthcare funding 30

Healthcare funding system 31

Australian drug regulatory system 32

Intellectual property rights 33

Understanding IPR in Australia: 33

Pricing and reimbursement 34

Cost-effectiveness 35

Reference pricing 36

New drug pricing reforms 36

Reimbursement in Australia 37

Chapter 4 Market analysis 40

Summary 40

Introduction 41

Biotechnology in Australia 41

Recent events in the Australian healthcare industry 44

Leading therapy areas 47

Therapy area sales forecast 51

Leading product dynamics 52

Lipitor – Pfizer 53

Crestor – AstraZeneca 54

Nexium – AstraZeneca 54

Lucentis – Novartis 54

Seretide – GSK 55

Zyprexa – Eli Lilly 56

Plavix – Sanofi-Aventis 56

Humira – Abbott 57

Efexor – Pfizer 57

Somac – Nycomed Pharma 58

Leading product sales forecast 59

Generics in Australia 60

Leading generic products in Australia 65

Leading drug classes in the Australian generic market 66

Chapter 5 Competitive landscape 68

Summary 68

Competitive positioning of top players in the Australian pharmaceutical market 69

Detailed analysis of key players in the Australian pharmaceutical market 70

Pfizer 70

Overview 70

Sales focus by leading therapeutic area 70

Marketed product portfolio 72

Pfizer's pipeline focus 73

Strategic growth analysis 75

AstraZeneca 77

Overview 77

Sales focus by leading therapeutic area 77

Marketed product portfolio 79

AstraZeneca's pipeline focus 80

Strategic growth analysis 81

Sanofi-Aventis 83

Overview 83

Sales focus by leading therapeutic area 83

Marketed product portfolio 85

Sanofi-Aventis' pipeline focus 86

Strategic growth analysis 87

Novartis 89

Overview 89

Sales focus by leading therapeutic area 90

Marketed product portfolio 91

Novartis' pipeline focus 92

Strategic growth analysis 94

GSK (GlaxoSmithKline) 95

Overview 95

Sales focus by leading therapeutic area 96

Marketed product portfolio 98

GSK's pipeline focus 99

Strategic growth analysis 101

Sigma Pharmaceuticals 102

Overview 102

Sales focus by leading therapeutic area 103

Marketed product portfolio 104

Sigma Pharmaceuticals' pipeline focus 105

Strategic growth analysis 105

Competitive positioning of leading generics players in Australia 106

Chapter 6 Appendix 110

Anatomical therapeutic classification (ATC) 110

A: Alimentary tract and metabolism 110

B: Blood and blood-forming organs 110

C: Cardiovascular system 110

D: Dermatologicals 110

G: Genitourinary system and sex hormones 111

H: Systemic hormonal preparations 111

J: General anti-infectives systemic 111

K: Hospital solutions 111

L: Antineoplastic and immunomodulating agents 111

M: Musculoskeletal system 112

N: Nervous system 112

P: Parasitology 112

R: Respiratory system 112

S: Sensory organs 112

T: Diagnostic agents 112

V: Various 112

Glossary 113

Index 115

List of Figures

Figure 2.1: Australian GDP distribution across different sectors, 2009 21

Figure 2.2: Comparison of healthcare expenditure across the major markets 25

Figure 3.3: Decision-making process for listing a drug on the PBS 35

Figure 4.4: Number of biotech companies in Australia by region, 2009 42

Figure 5.5: Pfizer's sales by therapeutic area in Australia ($m), 2009 71

Figure 5.6: AstraZeneca's sales by therapeutic area in Australia ($m), 2009 78

Figure 5.7: Sanofi-Aventis' sales by therapeutic area in Australia ($m), 2009 84

Figure 5.8: Novartis' sales by therapeutic area in Australia ($m), 2009 90

Figure 5.9: GSK's sales by therapeutic area in Australia ($m), 2009 97

Figure 5.10: Sigma Pharmaceuticals' sales by therapeutic area in Australia ($m), 2009 103

Figure 5.11: Positioning of top ten generics players in Australia, 2009 107

List of Tables

Table 2.1: Australia's key demographic indicators, 2009 20

Table 2.2: Key economic metrics in Australia, 2009 21

Table 2.3: DALYs (000s) in Australia, 2009–15 23

Table 2.4: DALYs (000s) in Australia for key diseases, 2009–15 24

Table 4.5: Key deals and alliances involving Australian pharmaceutical companies, 2009–10 46

Table 4.6: Leading therapy areas in Australia, 2009 47

Table 4.7: Leading drug classes within cardiovascular therapeutic area in Australia, 2009 48

Table 4.8: Leading drug classes within CNS therapeutic area in Australia, 2009 49

Table 4.9: Leading drug classes within alimentary tract and metabolism therapeutic area in Australia, 2009 50

Table 4.10: Leading drug classes within antineoplastic and immunomodulating agents in Australia, 2009 50

Table 4.11: Leading drug classes within respiratory therapeutic area in Australia, 2009 51

Table 4.12: Australian pharmaceutical market sales forecast by ATC code, 2009-15 52

Table 4.13: Leading brands in the Australian pharmaceutical market, 2009 53

Table 4.14: Leading products sales forecast, 2009–15 59

Table 4.15: Classification of the generic pharmaceutical market in Australia, 2009 62

Table 4.16: True generic pharmaceutical market in Australia in terms of value, 2009 ($m) 63

Table 4.17: True generic pharmaceutical market in Australia in terms of volume, 2009 (mSU) 64

Table 4.18: Leading true generic products in Australian pharmaceutical market, 2009 65

Table 4.19: Leading drug classes in the Australian generic pharmaceutical market, 2009 66

Table 5.20: Competitive positioning of top players in the Australian pharmaceutical market, 2009 69

Table 5.21: Pfizer's leading brands in the Australian pharmaceutical market, 2009 72

Table 5.22: Pfizer's late-stage R&D pipeline, 2010 74

Table 5.23: AstraZeneca's leading brands in the Australian pharmaceutical market, 2009 80

Table 5.24: AstraZeneca's late-stage R&D pipeline, 2010 81

Table 5.25: Sanofi-Aventis' leading brands in the Australian pharmaceutical market, 2009 85

Table 5.26: Sanofi-Aventis' late-stage R&D pipeline, 2009 87

Table 5.27: Novartis' leading brands in the Australian pharmaceutical market, 2009 91

Table 5.28: Novartis' late-stage R&D pipeline, 2010 93

Table 5.29: GSK's leading brands in the Australian pharmaceutical market, 2009 98

Table 5.30: GSK's late-stage R&D pipeline, 2010 100

Table 5.31: Sigma Pharmaceuticals' leading brands in the Australian pharmaceutical market, 2009 104

Table 5.32: Sigma Pharmaceuticals' late-stage R&D pipeline 105

Table 5.33: Leading generics players in Australian pharmaceutical market, 2009 ($m) 108

Table 5.34: Leading generics players in Australian pharmaceutical market, 2009 (mSU) 109

Companies mentioned

Pfizer , AstraZeneca , Sanofi-Aventis , Novartis , GSK , Sigma Pharmaceuticals

To order this report:

Pharmaceutical Industry: The Australian Pharmaceutical Market Outlook to 2015: Policy environment, market analysis, key trends, growth opportunities and competitive landscape

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com